Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13060890 | 1.00 | CTSL (0.41) | CTSLCTSSCTSKTAS1R3TAS1R1 | |
| SCHEMBL13005481 | 0.93 | CTSL (0.41) | CTSLCTSSCTSKTAS1R3TAS1R1 | |
| SCHEMBL13005472 | 0.93 | CTSL (0.41) | CTSLCTSSCTSKTAS1R3TAS1R1 | |
| SCHEMBL13060891 | 0.91 | TAS1R3 (0.44) | CTSLCTSSCTSKTAS1R3TAS1R1 | |
| SCHEMBL13060640 | 0.87 | TAS1R3 (0.40) | CTSLCTSSCTSKTAS1R3TAS1R1 | |
| SCHEMBL13061226 | 0.87 | ROCK2 (0.44) | CTSLHDAC4ROCK2ROCK1 | |
| SCHEMBL13060643 | 0.87 | ROCK2 (0.44) | CTSLHDAC4ROCK2ROCK1 | |
| SCHEMBL13060800 | 0.86 | TAS1R3 (0.41) | TAS1R3TAS1R1HDAC4ROCK2ROCK1 | |
| SCHEMBL13061114 | 0.86 | TAS1R3 (0.41) | TAS1R3TAS1R1HDAC4ROCK2ROCK1 | |
| SCHEMBL13005480 | 0.86 | TAS1R3 (0.42) | CTSLCTSSCTSKTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851637-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |